Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November
Key Highlights
- ➤Latigo management to join Guggenheim healthcare conference fireside chat November 10
- ➤Latigo management to join Jefferies healthcare conference fireside chat November 16
- ➤Onzotrigine is an oral Na(v)1.8 inhibitor targeting acute pain
- ➤LTG-321 is an oral Na(v)1.8 inhibitor targeting chronic musculoskeletal pain
THOUSAND OAKS, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced that management will participate in the following investor conferences: * Guggenheim 3(rd) Annual Healthcare Innovation Conference – Boston, MA Fireside chat on Tuesday, November 10, 2026, at 8:30 a.m. ET * Jefferies Global Healthcare Conference – London, UK Fireside chat on Monday, November 16, 2026, at 3:30 p.m. GMT The Latigo management team will also be available to participate in 1x1 meetings with investors who are registered to attend the conferences.
A replay of the webcasts will be available for 90 days and can be accessed by visiting the News & Events section of the Latigo Biotherapeutics website.
Get started
Create a free account to read the full story.